Label: CALCIUM GLUCONATE injection, solution

  • NDC Code(s): 44567-620-01, 44567-620-24, 44567-621-01, 44567-621-24, view more
    44567-622-01, 44567-622-24
  • Packager: WG Critical Care, LLC
  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: New Drug Application

Drug Label Information

Updated April 1, 2021

If you are a consumer or patient please visit this version.

  • HIGHLIGHTS OF PRESCRIBING INFORMATION
    These highlights do not include all the information needed to use CALCIUM GLUCONATE IN SODIUM CHLORIDE INJECTION safely and effectively. See full prescribing information for CALCIUM GLUCONATE IN SODIUM CHLORIDE INJECTION.

    CALCIUM GLUCONATE IN SODIUM CHLORIDE injection, for intravenous use
    Initial U.S. Approval: 1941

    INDICATIONS AND USAGE

    Calcium Gluconate in Sodium Chloride Injection is a form of calcium indicated for pediatric and adult patients for the treatment of acute symptomatic hypocalcemia. (1) (1)

    Limitations of Use: The safety of Calcium Gluconate Injection for long term use has not been established. (1) (1)

    DOSAGE AND ADMINISTRATION

    • Administer intravenously (bolus or continuous infusion) via a secure intravenous line (2.1) (2)

    • See Full Prescribing Information (FPI) for administration rates, and appropriate monitoring (2.1) (2)

    • Do not dilute Calcium Gluconate in Sodium Chloride Injection prior to use. Any unused portion should be discarded (2.1) (2)

    • Individualize the dose within the recommended range in adults and pediatric patients depending on the severity of symptoms of hypocalcemia, the serum calcium level, and the acuity of onset of hypocalcemia. See Table 1 in the FPI for dosing recommendations in mg of calcium gluconate for neonates, pediatric and adult patients. (2.2) (2)

    • Measure serum calcium during intermittent infusions every 4 to 6 hours and during continuous infusion every 1 to 4 hours. (2.3) (2)

    • Calcium Gluconate Injection is not physically compatible with fluids containing phosphate or bicarbonate. Precipitation may result if mixed. See FPI for all drug incompatibilities. (2.5) (2)

    DOSAGE FORMS AND STRENGTHS

    Injection: (3)

    • Calcium gluconate 1,000 mg per 50 mL (20 mg/mL) single-dose bag (3) (3)

    • Calcium gluconate 1,000 mg per 100 mL (10 mg/mL) single-dose bag (3) (3)

    • Calcium gluconate 2,000 mg per 100 mL (20 mg/mL) single-dose bag (3) (3)

    CONTRAINDICATIONS

    • Hypercalcemia (4) (4)

    • Neonates (28 days of age or younger) receiving ceftriaxone (4) (4)

    WARNINGS AND PRECAUTIONS

    Arrhythmias with Concomitant Cardiac Glycoside Use: If concomitant therapy is necessary, Calcium Gluconate in Sodium Chloride Injection should be given slowly in small amounts and close ECG monitoring is recommended (5.1) (5)

    End-Organ Damage due to Intravascular Ceftriaxone-Calcium Precipitates: Concurrent use of intravenous ceftriaxone may cause life-threatening precipitates. Do not administer ceftriaxone simultaneously with Calcium Gluconate in Sodium Chloride Injection via a Y-site in any age group. Cases of fatal outcomes in neonates have occurred. (4, 5.2) (5)

    Tissue Necrosis and Calcinosis: Calcinosis cutis can occur with or without extravasation of Calcium Gluconate in Sodium Chloride Injection. Tissue necrosis, ulceration, and secondary infection are the most serious complications. If extravasation occurs or clinical manifestations of calcinosis cutis are noted, immediately discontinue intravenous administration at that site and treat as needed. (5.3) (5)

    Hypotension, Bradycardia, and Cardiac Arrhythmias with Rapid Administration: To avoid adverse reactions that may follow rapid intravenous administration, Calcium Gluconate in Sodium Chloride Injection should be infused slowly, with careful ECG monitoring for cardiac arrhythmias. (5.4) (5)

    Aluminum Toxicity: This product contains aluminum, up to 25 mcg per liter, that may be toxic. (5.5) (5)

    ADVERSE REACTIONS

    The most common adverse events with Calcium Gluconate Injection are local soft tissue inflammation and necrosis, calcinosis cutis and calcification that are related to extravasation. Other adverse events include vasodilation, decreased blood pressure, bradycardia, cardiac arrhythmia, syncope, and cardiac arrest. (6)

    To report SUSPECTED ADVERSE REACTIONS, contact WG Critical Care, LLC at 1-866-562-4708 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

    DRUG INTERACTIONS

    Cardiac Glycoside: Synergistic arrhythmias may occur if calcium and cardiac glycosides are administered together. (7.1) (7)

    Calcium Channel Blockers: Administration of calcium may reduce the response. (7.2) (7)

    Drugs that may cause hypercalcemia: Vitamin D, vitamin A, thiazide diuretics, estrogen, calcipotriene and teriparatide administration may cause hypercalcemia. Monitor plasma calcium concentrations in patients taking these drugs concurrently. (7.3) (7)

    USE IN SPECIFIC POPULATIONS

    Geriatric use: Dosing in elderly patients should be cautious, usually starting at the low end of the dosage range. (8.5) (8)

    Renal impairment: Initiate with the lower limit of the dosage range and monitor serum calcium levels every 4 hours. (8.6, 2.4) (8)

    See 17 for PATIENT COUNSELING INFORMATION.

    Revised: 4/2021

  • Table of Contents
  • 1 INDICATIONS AND USAGE

    Calcium Gluconate in Sodium Chloride Injection is indicated for pediatric and adult patients for the treatment of acute symptomatic hypocalcemia.

    Limitations of Use

    The safety of Calcium Gluconate in Sodium Chloride Injection for long term use has not been established.

  • 2 DOSAGE AND ADMINISTRATION

    2.1 Important Administration Instructions

     
    See Table 1 for amounts of elemental calcium in Calcium Gluconate in Sodium Chloride Injection.

    Table 1. Amounts of Calcium Gluconate and Elemental Calcium

    Total Strength per Total Volume

    Strength per mL

    Elemental Calcium (mg) per mL

    Elemental Calcium (mEq) per mL

    Total Amount of Elemental Calcium (mg) per Total Volume

    Total Amount of Elemental Calcium (mEq) per Total Volume

    1,000 mg per 50 mL

    20 mg/mL

    1.86 mg

    0.093 mEq

    93 mg per 50 mL

    4.65 mEq per 50 mL

    1,000 mg per 100 mL

    10 mg/mL

    0.93 mg

    0.0465 mEq

    93 mg per 100 mL

    4.65 mEq per 100 mL

    2,000 mg per 100 mL

    20 mg/mL

    1.86 mg

    0.093 mEq

    186 mg per 100 mL

    9.3 mEq per 100 mL

    Do not dilute Calcium Gluconate in Sodium Chloride Injection prior to use. Any unused portion should be discarded.
    Inspect Calcium Gluconate in Sodium Chloride Injection visually prior to administration. The solution should appear clear and colorless. Do not administer if there is particulate matter or discoloration.
    Administer Calcium Gluconate in Sodium Chloride Injection intravenously via a secure intravenous line to avoid calcinosis cutis and tissue necrosis [see Warnings and Precautions (5.3)].

    Administer Calcium Gluconate in Sodium Chloride Injection by continuous infusion at the rate recommended in Table 1 [see Dosage and Administration (2.2)] and monitor patients, vitals, calcium and ECG during the infusion [see Warnings and Precautions (5.4)].

    2.2 Recommended Dosage

    Individualize the dose of Calcium Gluconate in Sodium Chloride Injection within the recommended range depending on the severity of symptoms of hypocalcemia, the serum calcium level, and the acuity of onset of hypocalcemia.

    Table 2 provides dosing recommendations for Calcium Gluconate in Sodium Chloride Injection in mg of calcium gluconate for neonates, pediatric and adult patients.

    Table 2. Dosing Recommendations in mg of Calcium Gluconate for Neonate, Pediatric, and Adult Patients

    PatientPopulation

    Initial Dose

    Subsequent Doses (if needed)

    Bolus

    Continuous Infusion

    Neonate (less than1 month to 1 month)

    100 mg/kg to 200 mg/kg

    100 mg/kg to 200 mg/kg every 6 hours

    Initiate at 17 mg/kg/hour to 33 mg/kg/hour

    Pediatric (greater than 1 month to less than 17 years)

    29 mg/kg to 60 mg/kg

    29 mg/kg to 60 mg/kg every 6 hours

    Initiate at 8 mg/kg/hour to 13 mg/kg/hour

    Adult (17 years and greater)

    1,000 mg to 2,000 mg

    1,000 mg to 2,000 mg every 6 hours

    Initiate at 5.4 mg/kg/hour to 21.5 mg/kg/hour

    For bolus administration, DO NOT exceed an infusion rate of:

     
    •200 mg/minute in adult patients
     
    •100 mg/minute in pediatric patients

    For continuous infusions, adjust rate as needed based on serum calcium levels

    2.3 Serum Calcium Monitoring

    Measure serum calcium every 4 to 6 hours during intermittent infusions with Calcium Gluconate in Sodium Chloride Injection and measure serum calcium every 1 to 4 hours during continuous infusion.

    2.4 Dosage in Renal Impairment

    For patients with renal impairment, initiate Calcium Gluconate in Sodium Chloride Injection at the lowest dose of the recommended dose ranges for all age groups and monitor serum calcium levels every 4 hours.

    2.5 Drug Incompatibilities

    • Do not mix Ca lc ium Gluc ona te in Sodium Chloride I njec tion with ceftr iax one . C onc urre nt use of intra ve nous cef tr iax one a nd Ca lc ium Gluc ona te in Sodium Chloride I njec tion ca n lea d to the f orma tion of cef tr iax one-calc ium prec ipita te s. C onc omitan t use of ceftr iax one a nd intra ve nous ca lc ium-c onta ining pr oduc ts is c ontra indica te d in ne onate s ( 28 day s of ag e or y ou nger ) [see Contraindications (4)] . I n pa tie nts olde r tha n 28 day s of age , cef tr iax one a nd ca lc ium-c onta ining pr oduc ts ma y be a dministered se que ntia lly , pr ovide d th e inf usion line s ar e thoro ug hl y f lushe d be twee n inf usions with a c ompa tible f luid. Cef tr iax one must n ot be a dministere d simulta ne ousl y with intra ve nou s ca lc ium-c onta inin g solutions via a Y- site in an y a ge gr oup [see Warnings and Precautions (5.2), Drug Interactions (7.3)].

    • Do not mix Ca lc ium Gluc ona te in Sodium Chloride I njec tion with f luids c onta ining bicar bonat e or phospha te . Ca lc ium Gluc ona te I njec tion is not phy sica ll y c ompa tible with fl uids c onta ining ph ospha te or bicar bona te . Prec ipita tion ma y re sult if mixe d.

     
    • Do not mix Ca lc ium Gluc ona te in Sodium Chloride I njec tion with minocyc line injec tion. Ca lc ium c omplexe s minocyc line re nder in g it inac tive.
  • 3 DOSAGE FORMS AND STRENGTHS

    Calcium Gluconate in Sodium Chloride Injection is a clear, colorless solution available as:

    Injection:

    • Calcium gluconate 1,000 mg per 50 mL (20 mg/mL) single-dose bag

    • Calcium gluconate 1,000 mg per 100 mL (10 mg/mL) single-dose bag

    • Calcium gluconate 2,000 mg per 100 mL (20 mg/mL) single-dose bag

  • 4 CONTRAINDICATIONS

    Calcium Gluconate in Sodium Chloride Injection is contraindicated in:

    •Hyperca lce mia

    • Ne ona te s ( 28 day s of a ge or y oun ger ) rece iving cef tr iax one [see Warnings and Precautions (5.2)]

  • 5 WARNINGS AND PRECAUTIONS

    5.1 Arrhythmias with Concomitant Cardiac Glycoside Use

    Cardiac arrhythmias may occur if calcium and cardiac glycosides are administered together. Hypercalcemia increases the risk of digoxin toxicity. Administration of Calcium Gluconate in Sodium Chloride Injection should be avoided in patients receiving cardiac glycosides. If concomitant therapy is necessary, Calcium Gluconate in Sodium Chloride Injection should be given slowly in small amounts and with close ECG monitoring [see Drug Interactions (7.1)].

    5.2 End-Organ Damage due to Intravascular Ceftriaxone-Calcium Precipitates

    Concomitant use of ceftriaxone and Calcium Gluconate in Sodium Chloride Injection is contraindicated in neonates (28 days of age or younger) due to cases of fatal outcomes in neonates in which a crystalline material was observed in the lungs and kidneys at autopsy after ceftriaxone and calcium were administrated simultaneously through the same intravenous line. Concomitant administration can lead to the formation of ceftriaxone-calcium precipitates that may act as emboli, resulting in vascular spasm or infarction [see Contraindications (4)].

    In patients older than 28 days of age, ceftriaxone and Calcium Gluconate in Sodium Chloride Injection may be administered sequentially, provided the infusion lines are thoroughly flushed between infusions with a compatible fluid. Do not administer Ceftriaxone simultaneously with Calcium Gluconate in Sodium Chloride Injection via a Y-site in any age group.

    5.3 Tissue Necrosis and Calcinosis

    Intravenous administration of Calcium Gluconate in Sodium Chloride Injection and local trauma may result in calcinosis cutis due to transient increase in local calcium concentration. Calcinosis cutis can occur with or without extravasation of Calcium Gluconate in Sodium Chloride Injection, is characterized by abnormal dermal deposits of calcium salts, and clinically manifests as papules, plaques, or nodules that may be associated with erythema, swelling, or induration. Tissue necrosis, ulceration, and secondary infection are the most serious complications.

    If extravasation occurs or clinical manifestations of calcinosis cutis are noted, immediately discontinue intravenous administration at that site and treat as needed.

    5.4 Hypotension, Bradycardia, and Cardiac Arrhythmias with Rapid Administration

    Rapid injection of Calcium Gluconate in Sodium Chloride Injection may cause vasodilation, decreased blood pressure, bradycardia, cardiac arrhythmias, syncope and cardiac arrest. To avoid adverse reactions that may follow rapid intravenous administration, Calcium Gluconate in Sodium Chloride Injection should be infused slowly. If rapid intravenous bolus of Calcium Gluconate Injection is required, the rate of intravenous administration should not exceed 200 mg/minute in adults and 100 mg/minute in pediatric patients and ECG monitoring during administration is recommended [see Dosage and Administration (2.1)].

    5.5 Aluminum Toxicity

    Calcium Gluconate in Sodium Chloride Injection contains aluminum, up to 25 mcg per liter, that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum. Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 mcg/kg/day to 5 mcg/kg/day accumulate aluminum levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.

  • 6 ADVERSE REACTIONS

    The following serious adverse reactions are also described elsewhere in the labeling:

    • Arrhythmias with Concomitant Cardiac Glycoside Use [see Warnings and Precautions (5.1)]

    • End-Organ Damage due to Intravascular Ceftriaxone-Calcium Precipitates [see Warnings and Precautions (5.2)]

    • Tissue Necrosis and Calcinosis [see Warnings and Precautions (5.3)]

    • Hypotension, Bradycardia, and Cardiac Arrhythmias [see Warnings and Precautions (5.4)]

    • Aluminum toxicity [see Warnings and Precautions (5.5)]

    The following adverse reactions associated with the use of calcium gluconate were identified in the literature. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency reliably or to establish a causal relationship to drug exposure.

    Cardiovascular: Vasodilation, decreased blood pressure, bradycardia, cardiac arrhythmia, syncope, cardiac arrest

    Administration site reactions: Local soft tissue inflammation, local necrosis, calcinosis cutis and calcification due to extravasation

  • 7 DRUG INTERACTIONS

    7.1 Cardiac Glycosides

    Hypercalcemia increases the risk of digoxin toxicity, while digoxin may be therapeutically ineffective in the presence of hypocalcemia. Synergistic arrhythmias may occur if calcium and cardiac glycosides are administered together. Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.

    7.2 Calcium Channel Blockers

    Administration of calcium may reduce the response to calcium channel blockers.

    7.3 Drugs that may cause Hypercalcemia

    Vitamin D, vitamin A, thiazide diuretics, estrogen, calcipotriene and teriparatide administration may cause hypercalcemia. Monitor plasma calcium concentrations in patients taking these drugs concurrently.

  • 8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy

    Risk summary

    Limited available data with Calcium Gluconate Injection use in pregnant women are insufficient to inform a drug associated risk of adverse developmental outcomes. There are risks to the mother and the fetus associated with hypocalcemia in pregnancy [see Clinical Considerations].

    The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

    Clinical Considerations

    Disease-associated maternal risk

    Maternal hypocalcemia can result in an increased rate of spontaneous abortion, premature and dysfunctional labor, and possibly preeclampsia.

    Fetal/Neonatal adverse reactions

    Infants born to mothers with hypocalcemia can have associated fetal and neonatal hyperparathyroidism, which in turn can cause fetal and neonatal skeletal demineralization, subperiosteal bone resorption, osteitis fibrosa cystica and neonatal seizures. Infants born to mothers with hypocalcemia should be carefully monitored for signs of hypocalcemia or hypercalcemia, including neuromuscular irritability, apnea, cyanosis and cardiac rhythm disorders.

    8.2 Lactation

    Risk summary

    Calcium is present in human milk as a natural component of human milk. It is not known whether intravenous administration of Calcium Gluconate in Sodium Chloride Injection can alter calcium concentration in human milk. There are no data on the effects of Calcium Gluconate Injection on the breastfed infant, or on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Calcium Gluconate in Sodium Chloride Injection and any potential adverse effects on the breastfed child from Calcium Gluconate in Sodium Chloride Injection or from the underlying maternal condition.

    8.4 Pediatric Use

    The safety and effectiveness of Calcium Gluconate in Sodium Chloride Injection have been established in pediatric patients for the treatment of acute, symptomatic hypocalcemia.

    Pediatric approval for Calcium Gluconate in Sodium Chloride Injection, including doses, is not based on adequate and well-controlled clinical studies. Safety and dosing recommendations in pediatric patients are based on published literature and clinical experience [see Dosage and Administration (2.2)].

    Concomitant use of ceftriaxone and Calcium Gluconate in Sodium Chloride Injection is contraindicated in neonates (28 days of age or younger) due to reports of fatal outcomes associated with the presence of lung and kidney ceftriaxone-calcium precipitates. In patients older than 28 days of age, ceftriaxone and Calcium Gluconate Injection may be administered sequentially, provided the infusion lines are thoroughly flushed between infusions with a compatible fluid [see Contraindications (4) and Warnings and Precautions (5.2)]. This product contains up to 25 mcg/L aluminum which may be toxic, particularly for premature neonates due to immature renal function. Parenteral administration of aluminum greater than 4 mcg/kg/day to 5 mcg/kg/day is associated with central nervous system and bone toxicity [see Warnings and Precautions (5.5)].

    8.5 Geriatric Use

    In general dose selection for an elderly patient should start at the lowest dose of the recommended dose range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

    8.6 Renal Impairment

    For patients with renal impairment, initiate Calcium Gluconate in Sodium Chloride Injection at the lowest dose of the recommended dose ranges across all age groups. Monitor serum calcium levels every 4 hours [see Dosage and Administration (2.4)].

    8.7 Hepatic Impairment

    Hepatic function does not impact the availability of ionized calcium after calcium gluconate intravenous administration. Dose adjustment in hepatically impaired patients may not be necessary.

  • 10 OVERDOSAGE

    Overdosage of Calcium Gluconate in Sodium Chloride Injection may result in hypercalcemia. Symptoms of hypercalcemia typically develop when the total serum calcium concentration is ≥12 mg/dL. Neurologic symptoms include depression, weakness, fatigue, and confusion at lower levels, with patients experiencing hallucinations, disorientation, hypotonicity, seizures, and coma. Effects on the kidney include diminished ability to concentrate urine and diuresis.

    If overdose of Calcium Gluconate in Sodium Chloride Injection occurs immediately discontinue administration and provide supportive treatments to restore intravascular volume as well as promote calcium excretion in the urine if necessary.

  • 11 DESCRIPTION

    Calcium Gluconate in Sodium Chloride Injection is a sterile, preservative-free, nonpyrogenic solution of calcium gluconate, a form of calcium, for intravenous use.

    Calcium Gluconate is calcium D-gluconate (1:2) monohydrate. The structural formula is:

    calcium gluconate structural formula

    Molecular formula: C12H22CaO14• H2O

    Molecular weight: 448.39

    Solubility in water: 3.5 g/100 mL at 25°C

    Calcium Gluconate in Sodium Chloride Injection is available as 1,000 mg per 50 mL (equivalent to 18.8 mg per mL calcium gluconate anhydrous) 1,000 mg per 100 mL (equivalent to 9.4 mg per mL calcium gluconate anhydrous) or 2,000 mg per 100 mL (equivalent to 18.8 mg per mL calcium gluconate anhydrous) in single-dose bags.

    Table 3. Calcium Gluconate Formulations

    1,000 mg per 50 mL

    1,000 mg per 100 mL

    2,000 mg per 100 mL

    Calcium Gluconate

    20 mg per mL

    10 mg per mL

    20 mg per mL

    Elemental Calcium

    1.86 mg per mL

    0.93 mg per mL

    1.86 mg per mL

    Sodium Chloride

    6.75 mg per mL

    8 mg per mL

    6.75 mg per mL

    Hydrochloric Acid or Sodium Hydroxide

    pH adjusted 6.0 to 8.2

  • 12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action

    Intravenous administration of calcium gluconate increases serum ionized calcium level. Calcium gluconate dissociates into ionized calcium in plasma. Ionized calcium and gluconate are constituents of body fluids.

    12.3 Pharmacokinetics

    Absorption

    Calcium Gluconate Injection is 100% bioavailable following intravenous injection.

    Metabolism

    Calcium itself does not undergo direct metabolism. The release of ionized calcium from intravenous administration of calcium gluconate is direct and does not seem to be affected by the first pass through the liver.

    Distribution

    Calcium in the body is distributed mainly in skeleton (99%). Only 1% of the total body calcium is distributed within the extracellular fluids and soft tissues. About 50% of total serum calcium is in the ionized form and represents the biologically active part. 8% to 10% serum calcium is bound to organic and inorganic acid and approximately 40% is protein-bound (primarily to albumin).

    Elimination

    Studies have shown a relationship between urinary calcium excretion and the intravenous administration of calcium gluconate, with a significant increase in urinary calcium excretion observed after the intravenous administration of calcium gluconate.

  • 13 NONCLINICAL TOXICOLOGY

    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

    Long-term studies in animals have not been conducted to evaluate the carcinogenic potential of Calcium Gluconate in Sodium Chloride Injection. Calcium gluconate was not mutagenic with or without metabolic activation in the Ames test with Salmonella typhimurium (strains TA-1535, TA-1537, and TA-1538) or Saccharomyces cerevisiae (Strain D4). Fertility studies in animals have not been conducted with calcium gluconate administered by the intravenous route.

  • 16 HOW SUPPLIED/STORAGE AND HANDLING

    Calcium Gluconate in Sodium Chloride Injection is a clear, colorless solution supplied in single-dose bags with an aluminum overwrap available as:

    Total Strength per Total Volume

    Strength per mL

    24 single-dose bags NDC

    Bag and Overwrap NDC

    1,000 mg per 50 mL

    20 mg/mL

    44567-620-24*

    44567-620-01

    1,000 mg per 100 mL

    10 mg/mL

    44567-622-24

    44567-622-01

    2,000 mg per 100 mL

    20 mg/mL

    44567-621-24

    44567-621-01

    *partial fill container 50 mL volume in a 100 mL container.

    Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Do not freeze. Product should be used within 60 days of removal from aluminum overwrap.

    Preservative-free. Discard any unused portion in the single-dose bag immediately.

  • 17 PATIENT COUNSELING INFORMATION

    Inform patients of the risks associated with infusion of Calcium Gluconate in Sodium Chloride Injection including local tissue inflammation, local necrosis and calcinosis. [see Warnings and Precautions (5.3)].

    Manufactured for:

    WG Critical Care, LLC

    Paramus, NJ 07652

    Made in Switzerland

  • PACKAGE/LABEL PRINCIPAL DISPLAY PANEL

    NDC 44567-620-24

    Calcium Gluconate in Sodium Chloride Injection 1,000 mg per 50 mL (20 mg/mL)

    Calcium Gluconate in Sodium Chloride Injection 1,000 mg per 50 mL image
  • Package/Label Display Panel

    NDC 44567-622-24

    Calcium Gluconate in Sodium Chloride Injection 1,000 mg per 100 mL (10 mg/mL)

    Calcium Gluconate in Sodium Chloride Injection 1,000 mg per 100 mL image
  • PACKAGE/LABEL PRINCIPAL DISPLAY PANEL

    NDC 44567-621-24

    Calcium Gluconate in Sodium Chloride Injection 2,000 mg per 100 mL (20 mg/mL)

    Calcium Glulconate in Sodium Chloride Injection 2,000 mg per 100 mL label image
  • INGREDIENTS AND APPEARANCE
    CALCIUM GLUCONATE 
    calcium gluconate injection, solution
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:44567-620
    Route of AdministrationINTRAVENOUS
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    CALCIUM GLUCONATE MONOHYDRATE (UNII: CZN0MI5R31) (CALCIUM CATION - UNII:2M83C4R6ZB) CALCIUM GLUCONATE MONOHYDRATE20 mg  in 1 mL
    Inactive Ingredients
    Ingredient NameStrength
    CALCIUM SACCHARATE (UNII: 6AP9J91K4V)  
    HYDROCHLORIC ACID (UNII: QTT17582CB)  
    SODIUM HYDROXIDE (UNII: 55X04QC32I)  
    SODIUM CHLORIDE (UNII: 451W47IQ8X)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:44567-620-2424 in 1 CARTON10/26/2018
    1NDC:44567-620-011 in 1 POUCH
    150 mL in 1 BAG; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    NDANDA21090610/26/2018
    CALCIUM GLUCONATE 
    calcium gluconate injection, solution
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:44567-622
    Route of AdministrationINTRAVENOUS
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    CALCIUM GLUCONATE MONOHYDRATE (UNII: CZN0MI5R31) (CALCIUM CATION - UNII:2M83C4R6ZB) CALCIUM GLUCONATE MONOHYDRATE10 mg  in 1 mL
    Inactive Ingredients
    Ingredient NameStrength
    CALCIUM SACCHARATE (UNII: 6AP9J91K4V)  
    HYDROCHLORIC ACID (UNII: QTT17582CB)  
    SODIUM HYDROXIDE (UNII: 55X04QC32I)  
    SODIUM CHLORIDE (UNII: 451W47IQ8X)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:44567-622-2424 in 1 CARTON07/13/2021
    1NDC:44567-622-011 in 1 POUCH
    1100 mL in 1 BAG; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    NDANDA21090607/13/2021
    CALCIUM GLUCONATE 
    calcium gluconate injection, solution
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:44567-621
    Route of AdministrationINTRAVENOUS
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    CALCIUM GLUCONATE MONOHYDRATE (UNII: CZN0MI5R31) (CALCIUM CATION - UNII:2M83C4R6ZB) CALCIUM GLUCONATE MONOHYDRATE20 mg  in 1 mL
    Inactive Ingredients
    Ingredient NameStrength
    CALCIUM SACCHARATE (UNII: 6AP9J91K4V)  
    HYDROCHLORIC ACID (UNII: QTT17582CB)  
    SODIUM HYDROXIDE (UNII: 55X04QC32I)  
    SODIUM CHLORIDE (UNII: 451W47IQ8X)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:44567-621-2424 in 1 CARTON10/26/2018
    1NDC:44567-621-011 in 1 POUCH
    1100 mL in 1 BAG; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    NDANDA21090610/26/2018
    Labeler - WG Critical Care, LLC (829274633)
    Registrant - WG Critical Care, LLC (829274633)
    Establishment
    NameAddressID/FEIBusiness Operations
    InfoRLife SA481732753MANUFACTURE(44567-620, 44567-622, 44567-621)